Exhaled nitric oxide correlates with experimental lung transplant rejection

Area of Science:

• Transplantation Immunology
• Pulmonary Medicine
• Biomarker Discovery

Background:

• Acute lung allograft rejection is associated with increased nitric oxide production.
• Transforming growth factor-beta1 (TGF-β1) is an immunosuppressive cytokine that can mitigate acute rejection.
• The study investigated the correlation between exhaled nitric oxide (eNO) and the severity of acute lung allograft rejection.

Purpose of the Study:

• To determine if exhaled nitric oxide (eNO) concentrations correlate with the degree of acute lung allograft rejection.
• To assess the potential of eNO as a noninvasive biomarker for monitoring lung transplant rejection.

Main Methods:

• A rat model of acute lung transplant rejection was established.
• Animals were divided into groups receiving partial immunosuppression with TGF-β1, fulminant acute rejection (no immunosuppression), full immunosuppression with cyclosporine, or serving as normal controls.
• Exhaled nitric oxide (eNO) concentrations were measured at sacrifice.

Main Results:

• Selective measurement from transplanted lungs showed significantly higher eNO in the fulminant rejection group (42.14 ± 7.27 ppb) compared to the partial immunosuppression group (8.61 ± 0.97 ppb) (p<0.001).
• Overall eNO measurements did not significantly differ between partial immunosuppression and fulminant rejection groups (p=0.58).
• eNO levels were lowest in the full immunosuppression (1.02 ± 0.21 ppb) and normal control groups (1.51 ± 0.74 ppb).

Conclusions:

• Exhaled nitric oxide (eNO) is elevated in fulminant acute lung allograft rejection.
• Partial immunosuppression with TGF-β1 significantly reduces eNO levels.
• eNO measurement correlates with acute lung transplant rejection severity and may serve as a noninvasive clinical monitoring tool.